TB/Flu-06E
The vaccine platform is based on the live influenza virus vector that is highly attenuated through alteration in NS1 protein function. This effect is achieved by the replacement of immunosuppressive C-terminal part of NS1 open reading frame with foreign sequences, encoding ESAT-6 antigen of M. tuberculosis. Importantly, viral vector itself acts as an adjuvant, stimulating…
Read MoreMip3a/relMtb
The Mip3a/relMtb vaccine is an intranasal therapeutic DNA fusion vaccine encoding the M. tuberculosis stringent response antigen relMtb (Rv2583c) linked to the immature dendritic cell–targeting chemokine Mip3a/CCL20, formulated as a plasmid DNA construct without an added adjuvant.
Read MoreALHA
Ag85A-LpqH (AL) is a recombinant subunit vaccine that combines the T cell-stimulating antigen Ag85A with the humoral immunity-targeting antigen LpqH. It is constructed using the pET-21a(+) vector, expressed in E. coli BL21(DE3), and formulated with aluminum for subcutaneous administration.
Read MoreTBvac-1, TBvac-2, TBvac-10
TBvac-1, TBvac-2, and TBvac-10 use a recombinant tri-segmented Pichinde virus (PICV) vector (rP18tri) to express M. tuberculosis antigens. TBvac-1 and TBvac-2 encode Ag85B, EsxA/ESAT-6, and EsxH/TB10.4, with antigen locations swapped between S1 and S2 segments. TBvac-10 encodes Ag85B, EsxH/TB10.4, RpfA, and Rv1733c. Vaccine stocks are produced in BHK-21 cells from plaque purified virus.
Read MoreRUTI®
RUTI® is a liposome suspension of the drug substance with a charge excipient. The drug substance is based on cell wall nanofragments of Mycobacterium tuberculosis. It contains a wide mixture of antigens obtained by a M. tuberculosis growth under stress conditions.
Read More